

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines).

A notice listing all currently HHS-certified laboratories and IITFs is published in the **Federal Register** during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at <http://www.samhsa.gov/workplace>.

**FOR FURTHER INFORMATION CONTACT:** Charles LoDico, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N02C, Rockville, Maryland 20857; 240-276-2600 (voice).

**SUPPLEMENTARY INFORMATION:** The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920).

The Mandatory Guidelines were initially developed in accordance with

Executive Order 12564 and section 503 of Public Law 100-71. The "Mandatory Guidelines for Federal Workplace Drug Testing Programs," as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated January 23, 2017 (82 FR 7920), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

#### HHS-Certified Instrumented Initial Testing Facilities

Dynacare, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-1190, (Formerly: Gamma-Dynacare Medical Laboratories).

#### HHS-Certified Laboratories

ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 844-486-9226.

Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.).

Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.).

Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock, AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).

Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS, 66215-2802, 800-445-6917.

DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-235-4890.

Dynacare\*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-1630, (Formerly: Gamma-Dynacare Medical Laboratories).

ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662-236-2609.

Laboratory Corporation of America Holdings, 7207 N Gessner Road, Houston, TX 77040, 713-856-8288/800-800-2387.

Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical Laboratories, Inc.).

Laboratory Corporation of America Holdings, 1904 TW Alexander Drive, Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group).

Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center).

LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.).

MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651-636-7466/800-832-3244.

Legacy Laboratory Services—MetroLab, 1225 NE 2nd Ave., Portland, OR 97232, 503-413-5295/800-950-5295.

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088. Testing for Veterans Affairs (VA) Employees Only.

National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661-322-4250/800-350-3515.

One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).

Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory).

Pathology Associates Medical Laboratories, 110 West Cliff Dr.,

Spokane, WA 99204, 509-755-8991/  
800-541-7891x7.

Phamatech, Inc., 15175 Innovation  
Drive, San Diego, CA 92128, 888-  
635-5840.

Quest Diagnostics Incorporated, 1777  
Montreal Circle, Tucker, GA 30084,  
800-729-6432, (Formerly: SmithKline  
Beecham Clinical Laboratories;  
SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 400  
Egypt Road, Norristown, PA 19403,  
610-631-4600/877-642-2216,  
(Formerly: SmithKline Beecham  
Clinical Laboratories; SmithKline Bio-  
Science Laboratories).

Redwood Toxicology Laboratory, 3700  
Westwind Blvd., Santa Rosa, CA  
95403, 800-255-2159.

STERLING Reference Laboratories, 2617  
East L Street, Tacoma, WA 98421,  
800-442-0438.

US Army Forensic Toxicology Drug  
Testing Laboratory, 2490 Wilson St.,  
Fort George G. Meade, MD 20755-  
5235, 301-677-7085, Testing for  
Department of Defense (DoD)  
Employees Only.

\* The Standards Council of Canada  
(SCC) voted to end its Laboratory  
Accreditation Program for Substance  
Abuse (LAPSA) effective May 12, 1998.  
Laboratories certified through that  
program were accredited to conduct  
forensic urine drug testing as required  
by U.S. Department of Transportation  
(DOT) regulations. As of that date, the  
certification of those accredited  
Canadian laboratories will continue  
under DOT authority. The responsibility  
for conducting quarterly performance  
testing plus periodic on-site inspections  
of those LAPSA-accredited laboratories  
was transferred to the U.S. HHS, with  
the HHS' NLCP contractor continuing to  
have an active role in the performance  
testing and laboratory inspection  
processes. Other Canadian laboratories  
wishing to be considered for the NLCP  
may apply directly to the NLCP  
contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to  
be qualified, HHS will recommend that  
DOT certify the laboratory (**Federal  
Register**, July 16, 1996) as meeting the  
minimum standards of the Mandatory  
Guidelines published in the **Federal  
Register** on January 23, 2017 (82 FR  
7920). After receiving DOT certification,  
the laboratory will be included in the  
monthly list of HHS-certified  
laboratories and participate in the NLCP  
certification maintenance program.

**Charles P. LoDico,**  
*Chemist.*

[FR Doc. 2018-16440 Filed 7-31-18; 8:45 am]

**BILLING CODE 4160-20-P**

## DEPARTMENT OF HOMELAND SECURITY

### U.S. Customs and Border Protection

[CBP Dec. 18-08]

#### COBRA Fees To Be Adjusted for Inflation in Fiscal Year 2019

**AGENCY:** U.S. Customs and Border  
Protection, Department of Homeland  
Security.

**ACTION:** General notice.

**SUMMARY:** This document announces  
that U.S. Customs and Border Protection  
(CBP) is adjusting certain customs user  
fees and limitations established by the  
Consolidated Omnibus Budget  
Reconciliation Act (COBRA) for Fiscal  
Year 2019 in accordance with the Fixing  
America's Surface Transportation Act  
(FAST Act) as implemented by CBP  
regulations.

**DATES:** The adjusted amounts of  
customs COBRA user fees and their  
corresponding limitations set forth in  
this notice for Fiscal Year 2019 are  
required as of October 1, 2018.

**FOR FURTHER INFORMATION CONTACT:** Tina  
Ghiladi, Director—Office of Finance,  
202-344-3722, *UserFeeNotices@  
cbp.dhs.gov*.

#### SUPPLEMENTARY INFORMATION:

##### Background

On December 4, 2015, the Fixing  
America's Surface Transportation Act  
(FAST Act, Pub. L. 114-94) was signed  
into law. Section 32201 of the FAST Act  
amended section 13031 of the  
Consolidated Omnibus Budget  
Reconciliation Act (COBRA) of 1985 (19  
U.S.C. 58c) by requiring certain customs  
COBRA user fees and corresponding  
limitations to be adjusted by the  
Secretary of the Treasury (Secretary) to  
reflect certain increases in inflation.

Sections 24.22 and 24.23 of title 19 of  
the Code of Federal Regulations (19 CFR  
24.22 and 24.23) describe the  
procedures that implement the  
requirements of the FAST Act.  
Specifically, paragraph (k) in section  
24.22 (19 CFR 24.22(k)) sets forth the  
methodology to determine the change in  
inflation as well as the factor by which  
the fees and limitations will be adjusted,  
if necessary. The fees and limitations  
subject to adjustment, which are set  
forth in Appendix A and Appendix B of  
part 24, include the commercial vessel  
arrival fees, commercial truck arrival  
fees, railroad car arrival fees, private  
vessel arrival fees, private aircraft  
arrival fees, commercial aircraft and  
vessel passenger arrival fees, dutiable  
mail fees, customs broker permit user

fees, barges and other bulk carriers  
arrival fees, and merchandise processing  
fees, as well as the corresponding  
limitations.

#### Determination of Whether an Adjustment Is Necessary for Fiscal Year 2019

In accordance with 19 CFR 24.22, CBP  
must determine annually whether the  
fees and limitations must be adjusted to  
reflect inflation. For fiscal year 2019,  
CBP is making this determination by  
comparing the average of the Consumer  
Price Index—All Urban Consumers, U.S.  
All items, 1982-84 (CPI-U) for the  
current year (June 2017-May 2018) with  
the average of the CPI-U for the  
comparison year (June 2016-May 2017)  
to determine the change in inflation, if  
any. If there is an increase in the CPI of  
greater than one (1) percent, CBP must  
adjust the customs COBRA user fees and  
corresponding limitations using the  
methodology set forth in 19 CFR  
24.22(k). (19 CFR 24.22(k)). Following  
the steps provided in paragraph (k)(2) of  
section 24.22, CBP has determined that  
the increase in the CPI between the most  
recent June to May 12-month period  
(June 2017-May 2018) and the  
comparison year (June 2016-May 2017)  
is 2.063<sup>1</sup> percent. As the increase in the  
CPI is greater than one (1) percent, the  
customs COBRA user fees and  
corresponding limitations must be  
adjusted for Fiscal Year 2019.

#### Determination of the Adjusted Fees and Limitations

Using the methodology set forth in  
section 24.22(k)(2) of the CBP  
regulations (19 CFR 24.22(k)), CBP has  
determined that the factor by which the  
base fees and limitations will be  
adjusted is 4.866 percent (base fees and  
limitations can be found in Appendix A  
and B to part 24 of title 19). In reaching  
this determination, CBP calculated the  
values for each variable found in  
paragraph (k) of 19 CFR 24.22 as  
follows:

- The arithmetic average of the CPI-U  
for June 2017-May 2018, referred to  
as (A) in the CBP regulations, is  
247.540;
- The arithmetic average of the CPI-U  
for Fiscal Year 2014, referred to as (B),  
is 236.009;
- The arithmetic average of the CPI-U  
for the comparison year, referred to as  
(C), is 242.328;
- The difference between the  
arithmetic averages of the CPI-U of the

<sup>1</sup> The figures provided in this notice may be  
rounded for publication purposes only. The  
calculations for the adjusted fees and limitations  
were made using unrounded figures, unless  
otherwise noted.